Skip to main content
SpringerLink
Log in

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

In this pilot clinical trial conducted in 10 postmenopausal women with advanced breast cancer, we evaluated the endocrine effects and toxicity of combined somatostatin analog and dopaminergic therapy in the attempt to suppress both growth hormone (GH) and prolactin (PRL) secretion. The patients' mean age was 63 years (range: 54–77) and the average number of previous treatments was 4.8 ± 2 (SD). All patients were treated with the somatostatin analog SMS 201-995 (100–200µg s.c. in a.m. and h.s.) and bromocriptine (2.5 mg orally twice a day). During treatment, GH levels following provocative testing (either L-DOPA or insulininduced hypoglycemia) were suppressed in 7/9 patients. Basal somatomedin-S (Sm-C) levels declined in 6/9 women. Both GH and Sm-C levels decreased in 4 patients, while in the remaining 5 only one of the two parameters was lowered on treatment. PRL secretion (during provocative TRH testing) was almost totally abolished in 8/9 patients. The treatment did not affect circulating levels of FSH, LH, E1, E2, E1-S, T4, T3RU, or cortisol. Seven patients experienced no side effects. Nausea occurred in 3, but was severe enough in only one to require discontinuation of therapy. One patient experienced disease stabilization consisting of < 50% regression of skin nodules and pleural effusion, a decline in CEA titer, and an improved performance status lasting 7 months. We conclude that combined SMS 201-995 and bromocriptine therapy is safe and frequently suppresses GH and PRL secretion. Its role in the treatment of metastatic breast cancer should be tested in patients with less advanced disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Manni A, Pearson OH: Antioestrogens in tumor therapy. Clin Oncol 1: 65–75, 1982

    Google Scholar 

  2. Lippman M, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976

    PubMed  Google Scholar 

  3. Nagasawa H: Prolactin and human breast cancer: a review. Eur J Cancer 15: 267–279, 1979

    PubMed  Google Scholar 

  4. Pearson OH, Manni A, Chambers M, Brodkey J, Marshall JS: The role of pituitary hormones in the growth of human breast cancer. Cancer Res 38: 4323–4326, 1978

    PubMed  Google Scholar 

  5. Holdaway IA, Friesen HG: Hormone binding by human mammary carcinoma. Cancer Res 37: 1946–1951, 1977

    PubMed  Google Scholar 

  6. Manni A, Wright C, David G, Glenn J, Joehl R, Feil P: Promotion by prolactin of the growth of human breast neoplasmsin vitro in the soft agar clonogenic assay. Cancer Res 46: 1669–1672, 1986

    PubMed  Google Scholar 

  7. Malarkey WB, Kennedy M, Allred LE, Milo G: Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. J Clin Endocrinol Metab 56: 673–677, 1983

    PubMed  Google Scholar 

  8. Biswas R, Vonderhaar BK: Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in longterm tissue culture. Cancer Res 47: 3509–3514, 1987

    PubMed  Google Scholar 

  9. Pearson OH, Manni A: Hormonal control of breast cancer growth in women and rats, In: Martini L, James VHT (eds): Current Topics in Experimental Endocrinology. Academic Press, New York, pp 75–92, 1978

    Google Scholar 

  10. Heuson JC, Coune A, Staquet M: Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancer. Eur J Cancer 8: 155–156, 1972

    PubMed  Google Scholar 

  11. Ch'ng LJC, Sandler LM, Kraenzlin ME, Burrin JM, Joplin GF, Bloom SR: Long term treatment of acromegaly with a long acting analogue of somatostatin. Brit Med J 290: 284–285, 1985

    Google Scholar 

  12. Barnard LB, Grantham WG, Lamberton P, O'Dorisio TM, Jackson IMD: Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995). Ann Int Med 105: 856–861, 1986

    PubMed  Google Scholar 

  13. Barkan AL, Kelch RP, Hopwood N, Beitins IZ: Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995. J Clin Endocrinol Metab 66: 16–23, 1988

    PubMed  Google Scholar 

  14. Peake GT, Morris J, Buckman MT: Growth hormone. In: Jaffe BM, Behrman HR (eds): Methods of Hormone Radioimmunoassay. Academic Press, New York, pp 223–224, 1979

    Google Scholar 

  15. Wass JAH, Clemmons DR, Underwood LE, Berrow I, Besser CM, Van Wyk JJ: Changes in circulating somatomedin-C levels in bromocriptine treated acromegaly. Clin Endocrinology 17: 369–373, 1982

    Google Scholar 

  16. Aubert NL, Becker BB, Raiti S: Report of the National Pituitary Agency collaborative study of the radioimmunoassay of prolactin. J Clin Endocrinol Metab 38: 1115–1120, 1974

    PubMed  Google Scholar 

  17. Santner SJ, Santen RJ, Kulin HE, Demers LM: A model for validation of RIA kit reagents. Measurement of FSH and LH in blood and urine. Clin Chem 27: 1892–1895, 1981

    PubMed  Google Scholar 

  18. Abraham GE, Manlimos FS, Garza R: Radioimmunoassay of steroids. In: Abraham GE (ed): Handbook of Radioimmunoassay. Marcel Dekker, New York. p 591, 1977

    Google Scholar 

  19. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells S: A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with avanced breast carcinoma. N Engl J Med 305: 545–551, 1981

    PubMed  Google Scholar 

  20. Demers LM, Derck DD: Comparison of competitive protein binding analysis and radioimmunoassay for the determination of cortisol in serum and urine. Clin Biochem 10: 104–108, 1977

    PubMed  Google Scholar 

  21. Demers LM, Abt WJ, Krieg AF: A new combined thyroid hormone index based on T4, T3 and resin uptake. Amer J Clin Path 65: 356–359, 1976

    Google Scholar 

  22. Bauer, Brinser U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J: SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133–1140, 1982

    PubMed  Google Scholar 

  23. Besser GM, Mortimer CH, Carr D, Schally AV, Coy DH, Evered D, Kastin AJ, Tunbridge WMG, Thorner MO, Hall R: Growth hormone release inhibiting hormone in acromegaly. Br Med J 1: 352–355, 1974

    PubMed  Google Scholar 

  24. Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E: The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60: 1161–1165, 1985

    PubMed  Google Scholar 

  25. del Pozo E, Neufeld M, Schulter K, Tortosa F, Clarenbach P, Bieder E, Wendel L, Nuesch E, Marbach P, Cramer H, Kerp L: Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol 111: 433–439, 1986

    PubMed  Google Scholar 

  26. Davies RR, Miller M, Turner SJ, Goodship THJ, Cook DB, Watson M, McGill A, Orskov H, Alberti KGMM, Johnston DG: Effects of somatostatin analogue SMS 201-995 in normal man. Clin Endocrinol 24: 665–674, 1986

    Google Scholar 

  27. Johnston DG, Davies RR, Alberti KGMM, Miller M, Turner SJ, Watson M: Effects of SMS 201-995 on intermediary metabolism and endocrine status in normal and diabetic humans. Amer J Med 81: 88–93, 1986

    PubMed  Google Scholar 

  28. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566–1570, 1987

    PubMed  Google Scholar 

  29. Mascardo RN, Sherline P: Somatostatin inhibits rapid intrasomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 111: 1394–1396, 1982

    PubMed  Google Scholar 

  30. Hierowski MT, Leibow C, Sapin K, Schally AV: Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 179: 252–256, 1985

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine, Pathology and Behavioral Science, The Milton S. Hershey Medical Center, The Pennsylvania State University, P.O. Box 850, 17033, Hershey, PA, USA

    Andrea Manni, Alice E. Boucher, Laurence M. Demers, Harold A. Harvey, Allan Lipton, Mary A. Simmonds & Mary Bartholomew

Authors
  1. Andrea Manni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alice E. Boucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence M. Demers
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Harold A. Harvey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Allan Lipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mary A. Simmonds
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mary Bartholomew
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Manni, A., Boucher, A.E., Demers, L.M. et al. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Tr 14, 289–298 (1989). https://doi.org/10.1007/BF01806300

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806300

Key words

Search

Navigation